公开(公告)号：WO2006034084A1

公开(公告)日：2006-03-30

申请号：PCT/US2005/033265

申请日：2005-09-19

Applicant: ABBOTT LABORATORIES ,  DZIKI, Walter ,  LU, Ziqi ,  RASMUSSEN, Michael, W. ,  WARDROP, Jaqueline ,  ZHANG, Geoff, G. ,  GOLDSTEIN, Mark ,  LINTON, Cathie, L.

Inventor： DZIKI, Walter ,  LU, Ziqi ,  RASMUSSEN, Michael, W. ,  WARDROP, Jaqueline ,  ZHANG, Geoff, G. ,  GOLDSTEIN, Mark ,  LINTON, Cathie, L.

IPC: C07D405/10 ,  A61K31/4025 ,  A61P35/00

CPC classification number: C07D405/10 ,  C07D405/04

Abstract: Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Abstract translation: 盐酸阿特拉森结晶形式2，含有它的组合物和治疗疾病的方法以及使用其抑制不良生理事件。

公开(公告)号：WO2006034094A1

公开(公告)日：2006-03-30

申请号：PCT/US2005/033278

申请日：2005-09-19

Applicant: ABBOTT LABORATORIES ,  DZIKI, Walter ,  LU, Ziqi ,  RASMUSSEN, Michael, W. ,  WARDROP, Jaqueline ,  ZHANG, Geoff, G. ,  GOLDSTEIN, Mark

Inventor： DZIKI, Walter ,  LU, Ziqi ,  RASMUSSEN, Michael, W. ,  WARDROP, Jaqueline ,  ZHANG, Geoff, G. ,  GOLDSTEIN, Mark

IPC: C07D405/10 ,  A61K31/4025 ,  A61P35/00

CPC classification number: A61K31/4025 ,  C07D405/10

Abstract: Atrasentan Hydrochloride Crystalline Form 1, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Abstract translation: 盐酸阿特拉森结晶形式1，含有它的组合物和治疗疾病的方法以及使用其抑制不良生理事件。

公开(公告)号：WO2002081441A1

公开(公告)日：2002-10-17

申请号：PCT/US2002/008074

申请日：2002-03-18

Applicant: ABBOTT LABORATORIES

Inventor： WITTENBERGER, Steven, J. ,  BHAGAVATULA, Lakshmi ,  DEGOEY, David, A. ,  DEMATTEI, John ,  HILL, David, R. ,  MCLAUGHLIN, Maureen, A. ,  GUPTA, Ashok, K. ,  MANNA, Sukumar ,  NICHOLS, Paul, J. ,  RAMIYA, Premchandran, H. ,  TIAN, Zhenping ,  RASMUSSEN, Michael, W.

IPC: C07D207/16

CPC classification number: C07D207/26 ,  C07D207/12 ,  C07D207/16

Abstract: A process for the preparation of neuraminidase inhibitors having structural formula (28) or therapeutically acceptable salts thereof, in which R1 is alkyl, cycloalkyl, cycloalkylalkyl, or arylalkyl; R2 is alkyl, cycloalkyl, cycloalkylalkyl, or arylalkyl; R4 is alkyl, cycloalkyalkyl, or aryl-(C2-C4-alkyl); R10 is methyl, ethyl, iso-propyl, or vinyl; and R12 is hydrogen or alkyl and intermediates useful for the process are disclosed.

Abstract translation: 制备具有结构式（28）或其治疗上可接受的盐的神经氨酸酶抑制剂的方法，其中R 1是烷基，环烷基，环烷基烷基或芳基烷基; R2是烷基，环烷基，环烷基烷基或芳基烷基; R4是烷基，环烷基或芳基 - （C 2 -C 4 - 烷基）; 甲基，乙基，异丙基或乙烯基; 并且R 12是氢或烷基，并且公开了可用于该方法的中间体。

公开(公告)号：EP1802610A1

公开(公告)日：2007-07-04

申请号：EP05796557.6

申请日：2005-09-19

Applicant: ABBOTT LABORATORIES

Inventor： DZIKI, Walter ,  LU, Ziqi ,  RASMUSSEN, Michael, W. ,  WARDROP, Jaqueline ,  ZHANG, Geoff, G. ,  GOLDSTEIN, Mark ,  LINTON, Cathie, L.

IPC: C07D405/10 ,  A61K31/4025 ,  A61P35/00

CPC classification number: C07D405/10 ,  C07D405/04

Abstract: Atrasentan Hydrochloride Crystalline Form 2, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Abstract translation: 公开了盐酸阿拉生坦晶型2，含有它的组合物以及使用它治疗疾病和抑制不利生理事件的方法。